S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:CRIS

Curis Competitors

$9.13
-0.58 (-5.97 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.64
Now: $9.13
$9.99
50-Day Range
$8.99
MA: $10.59
$12.80
52-Week Range
$0.62
Now: $9.13
$13.44
Volume2.38 million shs
Average Volume2.06 million shs
Market Capitalization$537.00 million
P/E RatioN/A
Dividend YieldN/A
Beta3.29

Competitors

Curis (NASDAQ:CRIS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying CRIS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Curis, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Curis (NASDAQ:CRIS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares Curis and Amgen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$10 million53.70$-32,140,000.00($0.86)-10.62
Amgen$23.36 billion5.49$7.84 billion$14.8214.97

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Curis and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curis00303.00
Amgen0111402.56

Curis presently has a consensus price target of $12.00, indicating a potential upside of 31.43%. Amgen has a consensus price target of $257.3043, indicating a potential upside of 15.95%. Given Curis' stronger consensus rating and higher probable upside, research analysts plainly believe Curis is more favorable than Amgen.

Insider & Institutional Ownership

34.7% of Curis shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 7.3% of Curis shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Curis and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curis-279.33%N/A-81.32%
Amgen29.42%95.55%15.52%

Summary

Amgen beats Curis on 9 of the 14 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

34.7% of Curis shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 7.3% of Curis shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Curis and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$10 million53.70$-32,140,000.00($0.86)-10.62
Gilead Sciences$22.45 billion3.54$5.39 billion$6.1410.30

Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Curis and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curis00303.00
Gilead Sciences1111202.46

Curis presently has a consensus price target of $12.00, indicating a potential upside of 31.43%. Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Curis.

Profitability

This table compares Curis and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curis-279.33%N/A-81.32%
Gilead Sciences5.48%37.77%12.76%

Summary

Gilead Sciences beats Curis on 10 of the 14 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares Curis and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$10 million53.70$-32,140,000.00($0.86)-10.62
Vertex Pharmaceuticals$4.16 billion12.98$1.18 billion$4.2948.44

Vertex Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

34.7% of Curis shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 7.3% of Curis shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Curis has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Curis and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curis-279.33%N/A-81.32%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Curis and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curis00303.00
Vertex Pharmaceuticals042212.89

Curis presently has a consensus price target of $12.00, suggesting a potential upside of 31.43%. Vertex Pharmaceuticals has a consensus price target of $292.68, suggesting a potential upside of 40.85%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Curis.

Summary

Vertex Pharmaceuticals beats Curis on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Regeneron Pharmaceuticals and Curis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
Curis00303.00

Regeneron Pharmaceuticals currently has a consensus target price of $625.8077, suggesting a potential upside of 39.26%. Curis has a consensus target price of $12.00, suggesting a potential upside of 31.43%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Curis.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Curis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.12$2.12 billion$21.4720.93
Curis$10 million53.70$-32,140,000.00($0.86)-10.62

Regeneron Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Curis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Curis-279.33%N/A-81.32%

Summary

Regeneron Pharmaceuticals beats Curis on 12 of the 15 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Curis and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curis00303.00
Biogen5151202.22

Curis currently has a consensus target price of $12.00, suggesting a potential upside of 31.43%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 15.52%. Given Curis' stronger consensus rating and higher probable upside, equities analysts plainly believe Curis is more favorable than Biogen.

Valuation and Earnings

This table compares Curis and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$10 million53.70$-32,140,000.00($0.86)-10.62
Biogen$14.38 billion2.79$5.89 billion$33.577.85

Biogen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Curis and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curis-279.33%N/A-81.32%
Biogen35.63%51.00%23.54%

Volatility and Risk

Curis has a beta of 3.29, suggesting that its share price is 229% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Insider & Institutional Ownership

34.7% of Curis shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 7.3% of Curis shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Biogen beats Curis on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Alexion Pharmaceuticals and Curis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017712.36
Curis00303.00

Alexion Pharmaceuticals presently has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Curis has a consensus price target of $12.00, suggesting a potential upside of 31.43%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Alexion Pharmaceuticals.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Curis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.54$2.40 billion$9.7415.24
Curis$10 million53.70$-32,140,000.00($0.86)-10.62

Alexion Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Curis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Curis-279.33%N/A-81.32%

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Curis on 10 of the 15 factors compared between the two stocks.


Curis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$221.91-0.9%$128.17 billion$23.36 billion17.90Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$63.23-0.8%$79.45 billion$22.45 billion65.19Analyst Downgrade
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$207.79-0.3%$54.02 billion$4.16 billion26.24
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$449.38-0.6%$48.14 billion$7.86 billion16.42
Biogen logo
BIIB
Biogen
1.9$263.57-1.1%$40.15 billion$14.38 billion8.72
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$148.46-0.2%$32.64 billion$4.99 billion34.69Unusual Options Activity
News Coverage
Seagen logo
SGEN
Seagen
1.7$145.45-1.7%$26.35 billion$916.71 million57.26Insider Selling
Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$121.02-4.6%$20.46 billion$876.29 million-54.76Analyst Upgrade
Insider Selling
Incyte logo
INCY
Incyte
1.9$77.50-1.9%$17.04 billion$2.16 billion-49.36
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.37-5.1%$16.07 billion$219.75 million-17.54
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$76.35-0.3%$13.88 billion$1.70 billion17.47Analyst Revision
Novavax logo
NVAX
Novavax
1.6$158.10-16.1%$10.06 billion$18.66 million-30.29Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
Repligen logo
RGEN
Repligen
1.7$183.21-9.1%$10.03 billion$270.24 million223.43Analyst Report
Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.97-2.2%$8.73 billion$788.10 million99.97Unusual Options Activity
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.27-3.0%$7.22 billion$1.12 billion106.81Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.34-1.8%$7.14 billion$1.45 billion15.17
Exelixis logo
EXEL
Exelixis
1.9$21.31-0.1%$6.65 billion$967.78 million44.40Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.41-3.8%$5.47 billion$195.99 million252.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$90.87-4.2%$4.84 billion$1.11 billion29.22Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$71.51-2.4%$4.31 billion$806.43 million-10.13Analyst Report
High Trading Volume
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.21-9.0%$3.98 billion$36.13 million-85.39Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Up
Alkermes logo
ALKS
Alkermes
1.4$18.21-2.4%$2.90 billion$1.17 billion-39.59Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.19-3.1%$2.81 billion$901.90 million-23.28
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.35-3.0%$2.74 billion$182.24 million-9.00Earnings Announcement
Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.71-4.3%$2.35 billion$120.28 million-143.14Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.43-1.2%$2.14 billion$638.60 million-10.93Analyst Report
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.08-0.0%$1.80 billionN/A-10.12Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.36-3.9%$1.67 billion$82.27 million-20.39
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$9.99-0.2%$1.61 billion$428.41 million14.48Insider Buying
Codexis logo
CDXS
Codexis
1.5$20.01-4.2%$1.19 billion$68.46 million-57.17Analyst Upgrade
Innoviva logo
INVA
Innoviva
1.4$11.06-0.1%$1.12 billion$261.02 million5.64
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$25.20-5.2%$997.09 million$3.57 million-11.30Gap Up
BOLT
Bolt Biotherapeutics
1.6$28.78-11.8%$993.54 millionN/A0.00Analyst Report
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$17.49-2.3%$959.90 million$227.19 million48.58Insider Selling
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.47-0.2%$959.28 million$35.22 million-6.18
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.31-8.6%$923.59 million$150,000.00-6.16Analyst Downgrade
MannKind logo
MNKD
MannKind
1.4$3.38-7.1%$835.39 million$63.04 million-16.09Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.66-7.8%$807.09 million$322.07 million-6.34Upcoming Earnings
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.33-7.3%$638.20 million$252 million-1.98Analyst Report
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-7.0%$604.95 million$59.29 million-23.87Earnings Announcement
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.66-1.9%$591.64 million$143.01 million-1.08
Geron logo
GERN
Geron
1.4$1.77-4.0%$549.54 million$460,000.00-5.06Upcoming Earnings
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.43-4.0%$521.13 million$22.27 million-5.11Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.20-2.5%$466.95 million$109.33 million-2.35
XOMA logo
XOMA
XOMA
1.8$35.35-2.3%$389.63 million$18.37 million-31.85Upcoming Earnings
Decrease in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.13-11.4%$386.99 million$36.63 million-4.86Analyst Upgrade
High Trading Volume
Verastem logo
VSTM
Verastem
1.5$2.22-2.7%$376.90 million$17.46 million-1.57Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.